NEW YORK, NY / ACCESSWIRE / February 3, 2023 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

ENVX Shareholders Click Here: https://www.zlk.com/pslra-1/enovix-lawsuit-submission-form?prid=36234&wire=1
YMAB Shareholders Click Here: https://www.zlk.com/pslra-1/y-mabs-therapeutics-loss-submission-form?prid=36234&wire=1
ALIZY Shareholders Click Here: https://www.zlk.com/pslra-1/allianz-se-class-action-submission-form?prid=36234&wire=1

* ADDITIONAL INFORMATION BELOW *

Enovix Corporation (NASDAQ:ENVX)

This lawsuit is on behalf of all investors who purchased or otherwise acquired Enovix common stock (or Rodgers Silicon Valley Acquisition Corp. common stock prior to July 15, 2021) between February 22, 2021 and January 3, 2023, inclusive.
Lead Plaintiff Deadline : March 7, 2023
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/enovix-lawsuit-submission-form?prid=36234&wire=1

According to the lawsuit, the Company made false and misleading statements to the market. Specifically, Enovix overstated its ability to produce batteries at commercial scale. Despite touting its 'meaningful progress' in developing its manufacturing capabilities, Enovix continued to face serious production problems. Based on these facts, the Company's public statements were false and materially misleading throughout the class period.

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

This lawsuit is on behalf of persons or entities who purchased shares of Y-mAbs Therapeutics, Inc. common stock on the open market or pursuant to registration statements filed with the U.S. Securities and Exchange Commission during the period October 6, 2020 through October 28, 2022, inclusive.
Lead Plaintiff Deadline : March 20, 2023
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/y-mabs-therapeutics-loss-submission-form?prid=36234&wire=1

According to the filed complaint, (i) Y-mAbs misrepresented the U.S. Food and Drug Administration's ('FDA') willingness to approve omburtamab, the Company's lead product candidate, for marketing based on the existing clinical trials; (ii) the Company misrepresented that progress was being made that would align with the FDA's requirements to demonstrate substantial evidence of effectiveness, sufficient for approval of omburtamab, through adequate and well-controlled studies; (iii) the FDA had repeatedly advised Y-mAbs that it was unlikely to grant approval for the marketing of omburtamab; and (iv) Y-mAbs had elected to submit the March 31, 2022 Biologics License Application prior to reaching agreement with the FDA on the content of the application.

Allianz SE (OTCMKT:ALIZY)

ALIZY Lawsuit on behalf of: investors who purchased March 9, 2018 - May 17, 2022
Lead Plaintiff Deadline : April 3, 2023
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/allianz-se-class-action-submission-form?prid=36234&wire=1

According to the filed complaint, during the class period, Allianz SE made materially false and/or misleading statements and/or failed to disclose that: (1) Allianz did not have effective internal controls; (2) Allianz's subsidiary was involved in substantial fraudulent activity; (3) as a result, Allianz was at an increased risk of regulatory scrutiny; (4) as a result, Allianz was at an increased risk of substantial losses and financial costs; and (5) as a result, defendants' public statements were materially false and misleading at all relevant times.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE : Levi & Korsinsky, LLP